Regulation Roles of MICA and NKG2D in Human Renal Cancer Cells

  • Jia, Hong-Ying (Clinical Molecular Biology Laboratory, the Second Hospital of Shandong University) ;
  • Liu, Jun-Li (Clinical Molecular Biology Laboratory, the Second Hospital of Shandong University) ;
  • Yuan, Ming-Zhen (Department of Urology, the Second Hospital of Shandong University) ;
  • Zhou, Cheng-Jun (Department of Pathology, the Second Hospital of Shandong University) ;
  • Sun, Wen-Dong (Department of Urology, the Second Hospital of Shandong University) ;
  • Zhao, Jing-Jie (Clinical Molecular Biology Laboratory, the Second Hospital of Shandong University) ;
  • Wang, Jue (Central Research Laboratory, the Second Hospital of Shandong University) ;
  • Liu, Ling (Clinical Molecular Biology Laboratory, the Second Hospital of Shandong University) ;
  • Luan, Yun (Central Research Laboratory, the Second Hospital of Shandong University)
  • Published : 2015.05.18


Objective: Our aim was to investigation the roles of MHC class I chain-related gene A(MICA) and natural killer cell group 2D(NKG2D) in human renal cancer cells. Materials and Methods: The expression of membrane MICA (mMICA) on renal cells and NKG2D on NK cells were detected by flow cytometry (FCM); the content of sMICA were detected by enzyme linked immunosorbent assay (ELISA) and the distribution of mMICA on renal tumor tissues by immunohistochemistry; the interaction between MICA and NKG2D was observed by antibody closed method. Results: Our results showed that the expression of mMICA in renal cancer tissues was significantly higher than in controls, where the soluble MICA was not expressed. Cytotoxic activity of NK cells was significantly reduced after exposure to NKG2D and MICA antibodies (P<0.05), and serum containing sMICA can obviously lower the function of NKG2D (P<0.05). Conclusions: The interaction of mMICA and NKG2D play important roles in mediation of cytotoxicity of NK cells in RCC. On the other hand, sMICA may mediate tumor immune escape through down- regulated NKG2D expression.


Renal cell carcinoma;MICA;NKG2D;NK cells;cytotoxicity


  1. Bae DS, Lee JK (2014). Development of NK cell expansion methods using feeder cells from human myelogenous leukemia cell line. Blood Res, 49, 154-61.
  2. Bae DS, Hwang YK, Lee JK (2012). Importance of NKG2D-NKG2D ligands interaction for cytolytic activity of natural killer cell. Cell Immunol, 276, 122-7.
  3. Coursey TG, Bohat R, Barbosa FL, Pflugfelder SC, de Paiva CS (2014). Desiccating stress-induced chemokine expression in the epithelium is dependent on upregulation of NKG2D/RAE-1 and release of IFN-${\gamma}$ in experimental dry eye. J Immunol, 15, 5264-72.
  4. Cho H, Chung JY, Kim S, et al (2014). MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer. BMC Cancer, 14, 957-61.
  5. Chen D, Gyllensten U (2014). MICA polymorphism: biology and importance in cancer. Carcinogenesis, 35, 2633-42.
  6. Cohen HT, McGovern FJ (2005). Renal-cell carcinoma. N Engl J Med, 353, 2477-90.
  7. Diefenbach A, Raulet DH (2002). The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev, 188, 9-21.
  8. Doubrovina ES, Doubrovin MM, Vider E, et al (2003). Evasion from NK cell immunity by MHC classes I chain-related molecules expressing colon adenocarcinoma. J Immunol, 171, 6891-9.
  9. Jia HY, Liu JL, Zhou CJ, et al (2014). High expression of MICA in human kidney cancer tissue and renal cell carcinoma lines. Asian Pac J Cancer Prev, 15, 1715-17.
  10. La Scaleia R, Stoppacciaro A, Oliva S, et al (2012). NKG2D/Ligand dysregulation and functional alteration of innate immunity cell populations in pediatric IBD. Inflamm Bowel Dis, 18, 1910-22.
  11. Lanier LL (2001). A renaissance for the tumor immunosurveillance hypothesis. Nat Med, 7, 1178-80.
  12. Matusali G, Tchidjou HK, Pontrelli G, et al (2013). Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells. FASEB J, 27, 2440-50.
  13. Meyer A, Carapito R, Ott L, et al (2014). High diversity of MIC genes in non-human primates. Immunogenetics, 66, 581-7.
  14. Noon AP1, Vlatkovic N, Polanski R, et al (2010). p53 and MDM2 in renal cell carcinoma:biomarkers for disease progression and future therapeutic targets? Cancer, 116, 780-90.
  15. Raulet DH (2003). Roles of the NKG2D immuno-receptor and its ligands. Nat Rev Immunol, 3, 781-90.
  16. Sconocchia G, Spagnoli GC, Del Principe D, et al (2009). Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves beta (2)-integrin mediated interaction. Neoplasia, 11, 662-71.
  17. Wang W, Guo H, Geng J, et al (2014). Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack. J Biol Chem, 289, 33311-9.
  18. Weissinger D, Tagscherer KE, Macher-Goppinger S, et al (2013). The soluble Decoy receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma. Mol Cancer, 12, 120-35.
  19. Yang F, Shao Y, Yang F, et al (2013). Valproic acid upregulates NKG2D ligand expression and enhances susceptibility of human renal carcinoma cells to NK cell mediated cytotoxicity. Arch Med Sci, 9, 323-31.

Cited by

  1. Tetramethypyrazine inhibits renal cell carcinoma cells through inhibition of NKG2D signaling pathways vol.49, pp.4, 2016,